154 related articles for article (PubMed ID: 9708599)
1. Elimination of over-the-counter medication coverage in the Oregon Medicaid population: the impact on program costs and drug use.
Zechnich AD; Greenlick M; Haxby D; Mullooly J
Med Care; 1998 Aug; 36(8):1283-94. PubMed ID: 9708599
[TBL] [Abstract][Full Text] [Related]
2. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
Gurwitz JH; McLaughlin TJ; Fish LS
Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
[TBL] [Abstract][Full Text] [Related]
3. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
Andrade SE; Gurwitz JH; Fish LS
Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
[TBL] [Abstract][Full Text] [Related]
4. Changing prescribing patterns and increasing prescription expenditures in Medicaid.
Fink KS; Byrns PJ
Ann Fam Med; 2004; 2(5):488-93. PubMed ID: 15506586
[TBL] [Abstract][Full Text] [Related]
5. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
Trygstad TK; Hansen RA; Wegner SE
J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
[TBL] [Abstract][Full Text] [Related]
7. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
8. The relationship of antidepressant prescribing concentration to treatment duration and cost.
Hodgkin D; Merrick EL; Hiatt D
J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
[TBL] [Abstract][Full Text] [Related]
9. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014.
Mahendraratnam N; Dusetzina SB; Farley JF
J Manag Care Spec Pharm; 2017 Mar; 23(3):355-363. PubMed ID: 28230452
[TBL] [Abstract][Full Text] [Related]
10. Over-the-counter drug use by medicare beneficiaries in nursing homes: implications for practice and policy.
Simoni-Wastila L; Stuart BC; Shaffer T
J Am Geriatr Soc; 2006 Oct; 54(10):1543-9. PubMed ID: 17038072
[TBL] [Abstract][Full Text] [Related]
11. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
13. Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting.
Fortess EE; Soumerai SB; McLaughlin TJ; Ross-Degnan D
J Am Geriatr Soc; 2001 Jun; 49(6):793-7. PubMed ID: 11454120
[TBL] [Abstract][Full Text] [Related]
14. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures.
Martin BC; McMillan JA
Med Care; 1996 Jul; 34(7):686-701. PubMed ID: 8676607
[TBL] [Abstract][Full Text] [Related]
15. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
[TBL] [Abstract][Full Text] [Related]
16. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
17. Controlling pharmacy costs in the NC Medicaid program.
Dobson LA
N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
[No Abstract] [Full Text] [Related]
18. Impact of interventions designed to increase market share and prescribing of fexofenadine at HMOs.
Benedetto SR; Sloan AS; Duncan BS
Am J Health Syst Pharm; 2000 Oct; 57(19):1778-85. PubMed ID: 11030030
[TBL] [Abstract][Full Text] [Related]
19. A critical analysis of studies of state drug reimbursement policies: research in need of discipline.
Soumerai SB; Ross-Degnan D; Fortess EE; Abelson J
Milbank Q; 1993; 71(2):217-52. PubMed ID: 8510601
[TBL] [Abstract][Full Text] [Related]
20. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
